Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 4.02B | 4.05B | 4.13B | 3.98B | 3.54B | 2.92B |
Gross Profit | 1.28B | 1.33B | 1.50B | 1.46B | 1.33B | 1.07B |
EBITDA | 546.00M | 581.14M | 1.03B | 1.04B | 854.29M | 759.15M |
Net Income | -31.56M | 10.30M | 474.62M | 486.23M | 390.98M | 364.30M |
Balance Sheet | ||||||
Total Assets | 7.58B | 7.53B | 8.20B | 7.60B | 7.02B | 5.49B |
Cash, Cash Equivalents and Short-Term Investments | 229.36M | 194.61M | 276.77M | 233.91M | 241.21M | 228.42M |
Total Debt | 2.99B | 2.72B | 3.07B | 3.10B | 2.92B | 2.14B |
Total Liabilities | 4.34B | 4.02B | 4.54B | 4.58B | 4.43B | 3.35B |
Stockholders Equity | 3.19B | 3.46B | 3.60B | 2.98B | 2.53B | 2.11B |
Cash Flow | ||||||
Free Cash Flow | 563.24M | 501.61M | 365.37M | 294.91M | 532.03M | 380.01M |
Operating Cash Flow | 776.39M | 734.58M | 683.90M | 619.64M | 760.80M | 546.58M |
Investing Cash Flow | -204.77M | -245.09M | -563.15M | -607.92M | -1.44B | -601.54M |
Financing Cash Flow | -674.60M | -550.93M | -85.52M | -42.40M | 672.60M | 47.25M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
82 Outperform | $42.66B | 49.01 | 59.33% | ― | 5.56% | 4.66% | |
79 Outperform | $19.94B | 22.58 | 13.35% | 1.79% | 9.38% | 6.43% | |
73 Outperform | $22.42B | ― | -18.66% | ― | 51.50% | 53.23% | |
72 Outperform | $10.28B | 115.09 | 2.67% | 2.78% | 3.31% | -72.63% | |
71 Outperform | $7.38B | 449.94 | -0.92% | ― | -2.16% | -107.31% | |
54 Neutral | $14.76B | ― | -23.82% | ― | -3.47% | 25.55% | |
48 Neutral | AU$2.44B | 3.89 | -64.25% | 2.90% | 35.15% | 13.63% |
On May 20, 2025, Charles River Laboratories extended the employment term of its CEO, James C. Foster, by an additional year, maintaining existing terms. During the same day, the company held its Annual Meeting of Shareholders, electing seven directors, appointing four new board members, and approving executive compensation and auditor appointments, while rejecting a proposal from PETA regarding non-human primate reports.
The most recent analyst rating on (CRL) stock is a Hold with a $235.00 price target. To see the full list of analyst forecasts on Charles River Labs stock, see the CRL Stock Forecast page.
On May 6, 2025, Charles River Laboratories entered a Cooperation Agreement with Elliott Investment Management, leading to the appointment of four new directors to its Board following the 2025 Annual Meeting. This strategic move includes a comprehensive review of the company’s business to enhance long-term shareholder value, with Elliott’s involvement signifying confidence in Charles River’s potential. The changes aim to optimize operations and drive efficiencies, with the new directors bringing significant industry expertise and fresh perspectives.